S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update (2012)

1. Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients’ beliefs and attitudes towards the disease. Br J Dermatol. 1996; 135: 533–7.

2. Schmid-Ott G, Malewski P, Kreiselmaier I, Mrowietz U. [Psychosocial consequences of psoriasis – an empirical study of disease burden in 3753 affected people]. Hautarzt. 2005; 56: 466–72.

3. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Jr., Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999; 41: 401–7.

4. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004; 9: 136–9.

5. Richards HL, Fortune DG, O’Sullivan TM, Main CJ, Griffiths CE. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol. 1999; 41: 581–3.

6. Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Archives of Dermatology. 2004; 140: 408–14.

7. Richards HL, Fortune DG, Griffiths CE. Adherence to treatment in patients with psoriasis. Journal of the European Academy of Dermatology & Venereology. 2006;

20: 370–9.

8. Nast A, Erdmann R, Pathirana D, Rzany B. Translating psoriasis treatment guidelines into clinical practice – the need for educational interventions and strategies for broad dissemination. J Eval Clin Pract. 2008; 14: 803–6.

9. Nast A, Reytan N, Rosumeck S, Erdmann R, Rzany B. Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry. J Eur Acad Dermatol Venereol. 2008; 22: 1337–42.

10. Berger K, Ehlken B, Kugland B, Augustin M. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges. 2005; 3: 511–8.

11. Traupe H, Robra BP. Gesundheitsberichterstattung des Bundes. Berlin: Robert-Koch-Institut, 2002: 1–15.

12. Radtke MA, Augustin M. Economic considerations in psoriasis management. Clin Dermatol. 2008; 26: 424–31.

13. Nast A, Augustin M, Boehncke WH, Klaus J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Schlaeger M, Sebastian M, Sterry W, Streit V, Weisenseel P, Rzany B. Evidence-based (S3) guideline for the treatment of psoriasis vulgaris – Update: “Therapeutic options” and “Efalizumab”. J Dtsch Dermatol Ges. 2010; 8: 65–6.

14. Nast A, Kopp I, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B. German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res. 2007; 299: 111–38.

15. Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B. [S3-Guidelines for the therapy of psoriasis vulgaris]. J Dtsch Dermatol Ges. 2006; 4 Suppl 2: S1–126.

16. Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B. Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges. 2007; 5 Suppl 3: 1–119.

17. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, Finlay AY, Griffiths CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009; 161: 987–1019.

18. Van Zuiden Communications (Hrsg.). Richtlijn foto(chemo)therapie en systemische therapie bij ernstige chronische plaque psoriasis. 2003.

19. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol. 2002; 146: 351–64.

20. Augustin M. Pharmako-Ökonomische Angaben. Stand Juli 2010.

21. Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. Acta Derm Venereol. 2010; 90: 147–51.

22. Griffiths CE, Christophers E, Barker JN, Chalmers RJ, Chimenti S, Krueger GG, Leonardi C, Menter A, Ortonne JP, Fry L. A classification of psoriasis vulgaris according to phenotype. British Journal of Dermatology. 2007; 156: 258–62.

23. Reich K, Kruger K, Mossner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009; 160: 1040–7.

24. Mrowietz U, Elder JT, Barker J. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Archives of Dermatological Research. 2006; 298: 309–19.

25. Mallbris L, Akre O, Granath F, Yin L, Lindelöf B, Ekbom A, Stahle-Bäckdahl M. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol. 2004; 19: 225–30.

26. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006; 296: 1735–41.

27. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, Giannetti A, Girolomoni G. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. British Journal of Dermatology. 2007; 157: 68–73.

28. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, Margolis DJ, Strom BL. The risk of mortality in patients with psoriasis: results from a population-based study. Archives of Dermatology. 2007; 143: 1493–9.

29. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Archives of Dermatological Research. 2006; 298: 321–8.

30. Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, Kaufmann R, Vogl TJ, Boehncke WH. Psoriasis: a possible risk factor for development of coronary artery calcification. British Journal of Dermatology. 2007; 156: 271–6.

31. Gerdes S, Mrowietz U. Impact of comorbidities on the management of psoriasis. Curr probl dermatol. 2009; 38: 21–36.

32. Schmitt J, Ford DE. Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population-based sample. Journal of the European Academy of Dermatology & Venereology. 2010; 24: 885–92.

33. Gudjonsson JE, Karason A, Antonsdottir A, Runarsdottir EH, Hauksson VB, Upmanyu R, Gulcher J, Stefansson K, Valdimarsson H. Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. British Journal of Dermatology. 2003; 148: 233–5.

34. Reich K, x00Fc, ffmeier U, x00F, nig IR, Lascorz J, Lohmann J, Wendler J, Traupe H, ssner R, Reis A, Burkhardt H. TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk allele. Arthritis & Rheumatism. 2007; 56: 2056–64.

35. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, Matsunami N, Ardlie KG, Civello D, Catanese JJ, Leong DU, Panko JM, McAllister LB, Hansen CB, Papenfuss J, Prescott SM, White TJ, Leppert MF, Krueger GG, Begovich AB. A

large-scale genetic association study confirms IL12B and leads to the identification

of IL23R as psoriasis-risk genes. American Journal of Human Genetics. 2007; 80: 273–90.

36. Capon F, Di Meglio P, Szaub J, Prescott NJ, Dunster C, Baumber L, Timms K, Gutin A, Abkevic V, Burden AD, Lanchbury J, Barker JN, Trembath RC, Nestle FO. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand

(IL12B) confer protection against psoriasis. Hum Genet. 2007; 122: 201–6.

37. Nestle FO, Kaplan DH, Barker J. Psoriasis. New England Journal of Medicine. 2009; 361: 496–509.

38. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Dauden E, Gisondi P, Iversen L, Kemeny L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Archives of Dermatological Research. 2010.

39. Schoffski O, Augustin M, Prinz J, Rauner K, Schubert E, Sohn S, Reich K. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges. 2007; 5: 209–18.

40. Schafer I, Hacker J, Rustenbach SJ, Radtke M, Franzke N, Augustin M. Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol. 2010; 20: 62–7.

41. Rychlik R, Rusche H, Augustin M. Systematik der Nutzenbewertung von Arzneimitteln. Gesundheitsökonomie & Qualitätsmanagement. 2004; 9: 245.

42. Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schafer I. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010; 162: 633–6.

43. Augustin M, Kruger K, Radtke MA, Schwippl I, Reich K. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology. 2008; 216: 366–72.

44. Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol. 2010; 62: 812–8.

45. Nelson AA, Pearce DJ, Fleischer AB, Jr., Balkrishnan R, Feldman SR. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol. 2008; 58: 125–35.

46. Schmitt-Rau K, Rosenbach T, Radtke M, Augustin M. Cost Effectiveness of Biologic Therapy in Remission Induction of Moderate to Severe Plaque Psoriasis. Dermatology. in press.

47. Augustin M, Peeters P, Radtke M, Moehling U, Lapp C. Cost-effectiveness model of topical treatment of mild to moderate psoriasis vulgaris in Germany. A comparison of calcipotriol/betamethasone (Daivobet/Dovobet/Taclonex) once daily and a morning/evening non-fix combination of calcipotriol and betamethasone. Dermatology. 2007; 215: 219–28.

48. Augustin M, Radtke M, van Engen A, Ruedig C, Lapp C, Moehling U. Pharmacoeconomic model of topical treatment options of mild to moderate psoriasis vulgaris in Germany. J Dtsch Dermatol Ges. 2009; 7: 329–38.

49. Anonymous. Salicylsäure zur topischen Anwendung. Bundesanzeiger. 19.06.1990, Korrektur 20.09.1990 (korrigierte Fassung in ZrvA Dez 1990).

50. Augustin M, Wulf A, Schloebe A, Zschocke I. Expertise zu Wirksamkeit und Nutzen von Harnstoff in der Therapie chronischer Hautkrankheiten. Wissenschaftliches Gutachten im Auftrag der Deutschen Dermatologischen Gesellschaft. Hamburg, 2004.

51. Braun-Falco O, Plewig G, Wolff HH. Dermatologie und Venerologie. 5. Edition. Springer, Berlin, 2005.

52. Camisa C. Handbook of Psoriasis. 2. Edition. Blackwell, Oxford, 2004.

53. Christophers E, Mrowietz U, Sterry W. Psoriasis – auf einen Blick. 1. Edition. Blackwell, Berlin, 2002.

54. Fritsch P. Dermatologie und Venerologie. 2. Edition. Springer, Berlin, 2004.

55. Katsambas AD, Lotti TM. European Handbook of Dermatological Treatments. 2. Edition. Springer, Berlin, 2003.

56. Korting HC, Sterry W. Therapeutische Verfahren in der Dermatologie. 1.Edition. Blackwell, Berlin, 2001.

57. Lebwohl M. The role of salicylic acid in the treatment of psoriasis. Int J Dermatol. 1999; 38: 16–24.

58. Lebwohl M, Heymann W, Berth-Jones J, Coulson I. Treatment of Skin Disease. 1. Edition. Mosby, London, 2002.

59. Müller-Oerlinghausen. Arzneimittelverordnungen. Im Auftrag der Arzneimittelkommission der Deutschen Ärzteschaft. Dt. Ärzteverlag, Köln, 2003.

60. Niedner R, Ziegenmeyer J. Dermatika. 1. Edition. Wiss. Verl.-Ges., Stuttgart, 1992.

61. Orfanos CE, Garbe C. Therapie der Hautkrankheiten. 2. Edition. Springer, Berlin, 2002.

62. Traupe H, Hamm H. Pädiatrische Dermatologie. 1. Edition. Springer, Berlin, 1999.

63. Van de Kerkhof P. Textbook of Psoriasis. 2. Edition. Blackwell, Oxford, 2003.

64. Going SM, Guyer BM, Jarvie DR, Hunter JA. Salicylic acid gel for scalp psoriasis. Clin Exp Dermatol. 1986; 11: 260–2.

65. Hagemann I, Proksch E. Topical treatment by urea reduces epidermal hyperproliferation and induces differentiation in psoriasis. Acta Derm Venereol. 1996; 76: 353–6.

66. Ross SD, Schachter RK. A randomized comparison of three conventional modes of treatment of psoriasis of the scalp. Cutis. 1981; 28: 438–9.

67. Swanbeck G. A new treatment of ichthyosis and other hyperkeratotic conditions. Acta Derm Venereol. 1968; 48: 123–7.

68. Mrowietz U, Graeber M, Brautigam M, Thurston M, Wagenaar A, Weidinger G, Christophers E. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol. 1998; 139: 992–6.

69. Remitz A, Reitamo S, Erkko P, Granlund H, Lauerma AI. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol. 1999; 141: 103–7.

70. Zonneveld IM, Rubins A, Jablonska S, Dobozy A, Ruzicka T, Kind P, Dubertret L, Bos JD. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol. 1998; 134: 1101–2.

71. Amichai B. Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream. J Eur Acad Dermatol Venereol. 2004; 18: 742–3.

72. Freeman AK, Linowski GJ, Brady C, Lind L, Vanveldhuisen P, Singer G, Lebwohl M. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol. 2003; 48: 564–8.

73. Gribetz C, Ling M, Lebwohl M, Pariser D, Draelos Z, Gottlieb AB, Zaias N, Chen DM, Parneix-Spake A, Hultsch T, Menter A. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol. 2004; 51: 731–8.

74. Anonymous. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. The European FK 506 Multicentre Study Group. Arch Dermatol. 1996; 132: 419–23.

75. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, Schuler W, Schulz M, Werner FJ, Winiski A, Wolff B, Zenke G. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J

Dermatol. 1999; 141: 264–73.

76. O’Keefe SJ, Tamura J, Kincaid RL, Tocci MJ, O’Neill EA. FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature. 1992; 357: 692–4.

77. Liu J, Farmer JD, Jr., Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991; 66: 807–15.

78. Sperr WR, Agis H, Czerwenka K, Virgolini I, Bankl HC, Muller MR, Zsebo K, Lechner K, Valent P. Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells. J Allergy Clin Immunol. 1996; 98: 389–99.

79. Kalthoff FS, Chung J, Musser P, Stuetz A. Primecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids. Clin Exp Immunol. 2003; 133: 350–9.

80. Schuller E, Oppel T, Bornhovd E, Wetzel S, Wollenberg A. Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis. J Allergy Clin Immunol. 2004; 114: 137–43.

81. Liao YH, Chiu HC, Tseng YS, Tsai TF. Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a doubleblind, randomized controlled trial. Br J Dermatol. 2007; 157: 1005–12.

82. Carroll CL, Clarke J, Camacho F, Balkrishnan R, Feldman SR. Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch Dermatol. 2005; 141: 43–6.

83. Ortonne JP, van de Kerkhof PC, Prinz JC, Bieber T, Lahfa M, Rubins A, Wozel G, Lorette G. 0.3% Tacrolimus gel and 0.5% Tacrolimus cream show efficacy in mild to moderate plaque psoriasis: Results of a randomized, open-label, observer-blinded

study. Acta Derm Venereol. 2006; 86: 29–33.

84. Martin Ezquerra G, Sanchez Regana M, Herrera Acosta E, Umbert Millet P. Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques. J Drugs Dermatol. 2006; 5: 334–6.

85. Mrowietz U, Wustlich S, Hoexter G, Graeber M, Brautigam M, Luger T. An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta Derm Venereol. 2003; 83: 351–3.

86. Mrowietz U, Falsafi M, Schroder JM, Christophers E. Inhibition of human monocyte functions by anthralin. Br J Dermatol. 1992; 127: 382–6.

87. Schroder JM, Kosfeld U, Christophers E. Multifunctional inhibition by anthralin in nonstimulated and chemotactic factor stimulated human neutrophils. J Invest Dermatol. 1985; 85: 30–4.

88. Anderson R, Lukey PT, Dippenaar U, Eftychis HA, Findlay GH, Wooten MW, Nel AE. Dithranol mediates pro-oxidative inhibition of polymorphonuclear leukocyte migration and lymphocyte proliferation. Br J Dermatol. 1987; 117: 405–18.

89. Fisher LB, Maibach HI. The effect of anthralin and its derivatives on epidermal cell kinetics. J Invest Dermatol. 1975; 64: 338–41.

90. Gottlieb AB, Khandke L, Krane JF, Staiano-Coico L, Ashinoff R, Krueger JG. Anthralin decreases keratinocyte TGF-alpha expression and EGF-receptor binding in vitro. J Invest Dermatol. 1992; 98: 680–5.

91. Kemeny L, Michel G, Arenberger P, Ruzicka T. Down-regulation of epidermal growth factor receptors by dithranol. Acta Derm Venereol. 1993; 73: 37–40.

92. Ockenfels HM, Nussbaum G, Schultewolter T, Burger PM, Goos M. Cyclosporin A, FK506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes. Arch Dermatol Res. 1995; 287: 304–9.

93. Lebwohl M. Anthralin. Dermatol Ther. 1999; 11: 8–13.

94. Silverman A, Menter A, Hairston JL. Tars and anthralins. Dermatol Clin. 1995; 13: 817–33.

95. Goodfield MJ, Hull SM, Cunliffe WJ. The systemic effect of dithranol treatment in psoriasis. Acta Derm Venereol. 1994; 74: 295–7.

96. Monastirli A, Georgiou S, Pasmatzi E, Sakkis T, Badavanis G, Drainas D, Sagriotis A, Tsambaos D. Calcipotriol plus short-contact dithranol: a novel topical combination therapy for chronic plaque psoriasis. Skin Pharmacol Appl Skin Physiol. 2002; 15: 246–51.

97. Agrup G, Agdell J. A comparison between Antraderm stick (0.5% and 1%) and dithranol paste (0.125% and 0.25%) in the treatment of psoriasis. Br J Clin Pract. 1985; 39: 185–7.

98. de Mare S, Calis N, den Hartog G, van Erp PE, van de Kerkhof PC. The relevance of salicylic acid in the treatment of plaque psoriasis with dithranol creams. Skin Pharmacol. 1988; 1: 259–64.

99. Gerritsen MJ, Boezeman JB, Elbers ME, van de Kerkhof PC. Dithranol embedded in crystalline monoglycerides combined with phototherapy (UVB): a new approach in the treatment of psoriasis. Skin Pharmacol Appl Skin Physiol. 1998; 11: 133–9.

100. Hutchinson PE, Marks R, White J. The efficacy, safety and tolerance of calcitriol 3 microg/g ointment in the treatment of plaque psoriasis: a comparison with short-contact dithranol. Dermatology. 2000; 201: 139–45.

101. Mahrle G, Schulze HJ. [The effect of initial external glucocorticoid administration on cignolin treatment of psoriasis]. Z Hautkr. 1990; 65: 282, 85–7.

102. Prins M, Swinkels OQ, Bouwhuis S, de Gast MJ, Bouwman-Boer Y, van der Valk PG, van de Kerkhof PC. Dithranol in a cream preparation: disperse or dissolve? Skin Pharmacol Appl Skin Physiol. 2000; 13: 273–9.

103. Prins M, Swinkels OQ, Van de Kerkhof PC, Van der Valk PG. The impact of the frequency of short contact dithranol treatment. Eur J Dermatol. 2001; 11: 214–8.

104. Swinkels OQ, Prins M, Kucharekova M, de Boo T, Gerritsen MJ, van der Valk PG, van de Kerkhof PC. Combining lesional short-contact dithranol therapy of psoriasis with a potent topical corticosteroid. Br J Dermatol. 2002; 146: 621–6.

105. Thune P, Brolund L. Short- and longcontact therapy using a new dithranol formulation in individually adjusted dosages in the management of psoriasis. Acta Derm Venereol Suppl (Stockh). 1992; 172: 28–9.

106. Van de Kerkhof PC, Green C, Hamberg KJ, Hutchinson PE, Jensen JK, Kidson P, Kragballe K, Larsen FG, Munro CS, Tillman DM. Safety and efficacy of combined high-dose treatment with calcipotriol ointment and solution in patients with psoriasis. Dermatology. 2002; 204: 214–21.

107. van de Kerkhof PC, van der Valk PG, Swinkels OQ, Kucharekova M, de Rie MA, de Vries HJ, Damstra R, Oranje AP, de Waard-van der Spek FB, van Neer P, Lijnen RL, Kunkeler AC, van Hees C, Haertlein NG, Hol CW. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting. Br J Dermatol. 2006; 155: 800–7.

108. Agarwal R, Saraswat A, Kaur I, Katare OP, Kumar B. A novel liposomal formulation of dithranol for psoriasis: preliminary results. J Dermatol. 2002; 29: 529–32.

109. Mork NJ, Austad J, Brolund L. An open, parallel groups, study of the importance of thoroughness of application in the treatment of psoriasis with a dithranol cream (Micanol). Acta Derm Venereol Suppl (Stockh). 1992; 172: 23–4.

110. Berth-Jones J, Chu AC, Dodd WA, Ganpule M, Griffiths WA, Haydey RP, Klaber MR, Murray SJ, Rogers S, Jurgensen HJ. A multicentre, parallelgroup comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol. 1992; 127: 266–71.

111. Haustein UF, Lohrisch I. Irritant potential of dithranol. Dermatologica. 1986; 173: 288–93.

112. Mustakallio KK. Irritation and staining by dithranol (anthralin) and related compounds: I. Estimation with chamber testing and contact thermography. Acta Derm Venereol Suppl (Stockh). 1979; 59: 125–32.

113. Schiavi ME, Belletti B, Seidenari S. Ultrasound description and quantification

of irritant reactions induced by dithranol at different concentrations. A comparison with visual assessment and colorimetric measurements. Contact Dermatitis. 1996; 34: 272–7.

114. Burden AD, Muston H, Beck MH. Intolerance and contact allergy to tar and dithranol in psoriasis. Contact Dermatitis. 1994; 31: 185–6.

115. Rotstein H, Baker C. The treatment of psoriasis. Med J Aust. 1990; 152: 153–64.

116. Camarasa JM, Ortonne JP, Dubertret L. Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy. J Dermatolog Treat. 2003; 14: 8–13.

117. Chuang TY, Samson CR. Clinical efficacy and safety of augmented betamethasone dipropionate ointment and diflorasone ointment for psoriasis – A multicentre, randomized, double-blinded study. J Dermatol Treat. 1991; 2: 63–6.

118. Douglas WS, Poulin Y, Decroix J, Ortonne JP, Mrowietz U, Gulliver W, Krogstad AL, Larsen FG, Iglesias L, Buckley C, Bibby AJ. A new calcipotriol/ betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol. 2002; 82: 131–5.

119. Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg. 2003; 7: 185–92.

120. Katz HI, Tanner DJ, Cuffie CA, Brody NI, Garcia CJ, Lowe NJ, Medansky RS, Roth HL, Shavin JS, Swinyer LJ. A comparison of the efficacy and safety of the combination mometasone furoate 0.1%/salicylic acid 5% ointment with each of its components in psoriasis. J Derm Treat. 1998; 9: 151–6.

121. Kaufmann R, Bibby AJ, Bissonnette R, Cambazard F, Chu AC, Decroix J, Douglas WS, Lowson D, Mascaro JM, Murphy GM, Stymne B. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology. 2002; 205: 389–93.

122. Koo J, Cuffie CA, Tanner DJ, Bressinck R, Cornell RC, DeVillez RL, Edwards L, Breneman DL, Piacquadio DJ, Guzzo CA, Monroe EW. Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study. Clin Ther. 1998; 20: 283–91.

123. Lowe N, Feldman SR, Sherer D, Weiss J, Shavin JS, Lin YL, Foley V, Soto P. Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis. J Dermatolog Treat. 2005; 16: 158–64.

124. Papp KA, Guenther L, Boyden B, Larsen FG, Harvima RJ, Guilhou JJ, Kaufmann R, Rogers S, van de Kerkhof PC, Hanssen LI, Tegner E, Burg G, Talbot D, Chu A. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003;

48: 48–54.

125. Jarratt MT, Clark SD, Savin RC, Swinyer LJ, Safley CF, Brodell RT, Yu K. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis. Cutis. 2006; 78: 348–54.

126. Bagatell F. Management of psoriasis: A clinical evaluation of the dermatological

patch, Actidermregistered trade mark, over a topical steroid. Adv Therap. 1988; 5: 291–96.

127. Beutner K, Chakrabarty A, Lemke S, Yu K. An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis. J Drugs Dermatol. 2006; 5: 357–60.

128. Decroix J, Pres H, Tsankov N, Poncet M, Arsonnaud S. Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis. Cutis. 2004; 74: 201–6.

129. Housman TS, Keil KA, Mellen BG, McCarty MA, Fleischer AB, Jr., Feldman SR. The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis. J Am Acad Dermatol. 2003; 49: 79–82.

130. Koo J, Blum RR, Lebwohl M. A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes. J Am Acad Dermatol. 2006; 55: 637–41.

131. Lebwohl M, Sherer D, Washenik K, Krueger GG, Menter A, Koo J, Feldman SR. A randomized, doubleblind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol. 2002; 41: 269–74.

132. Medansky RS, Cuffie CA, Tanner DJ. Mometasone furoate 0.1%-salicylic acid 5% ointment twice daily versus fluocinonide 0.05% ointment twice daily in the management of patients with psoriasis. Clin Ther. 1997; 19: 701–9.

133. Menter A, Abramovits W, Colon LE, Johnson LA, Gottschalk RW. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis. J Drugs Dermatol. 2009; 8: 52–7.

134. Pacifico A, Daidone R, Peris K. A new formulation of an occlusive dressing containing betamethasone valerate 0.1% in the treatment of mild to moderate psoriasis. J Eur Acad Dermatol Venereol. 2006; 20: 153–7.

135. Peharda V, Gruber F, Prpic L, Kastelan M, Brajac I. Comparison of mometasone

fluroate 0.1% ointment and betamethasone dipropionate 0.05% ointment in the treatment of psoriasis vulgaris. Acta Derm Venereol Croatica. 2000; 8: 223–6.

136. Rosina P, Giovannini A, Gisondi P, Girolomoni G. Microcirculatory modifications of psoriatic lesions during topical therapy. Skin Res Technol. 2009; 15: 135–8.

137. Shupack JL, Jondreau L, Kenny C, Stiller MJ. Diflorasone diacetate ointment 0.05% versus betamethasone dipropionate ointment 0.05% in moderate-severe plaque-type psoriasis. Dermatology. 1993; 186: 129–32.

138. Stein LF, Sherr A, Solodkina G, Gottlieb AB, Chaudhari U. Betamethasone valerate foam for treatment of nonscalp psoriasis. J Cutan Med Surg. 2001; 5: 303–7.

139. Svensson AR, Gisslen H, Nordin P, Gios I. A comperative study of mometasone furoate ointment and betamethasone valerate ointment in patients with psoriasis vulgaris. Curr Ther Res Clin Exp. 1992; 52: 390–96.

140. Tabolli S, Alessandroni L, Didona B, Di Pietro C, Gisondi P, Rota L, Sampogna F, Abeni D. A randomized controlled trial to evaluate short-term treatment with eosin vs. topical steroids in psoriasis. Clin Exp Dermatol. 2009; 34: 304–8.

141. Weston WL, Fennessey PV, Morelli J, Schwab H, Mooney J, Samson C, Huff L, Harrison LM, Gotlin R. Comparison of hypothalamus-pituitary-adrenal axis suppression from superpotent topical steroids by standard endocrine function testing and gas chromatographic mass spectrometry. J Invest Dermatol. 1988; 90: 532–5.

142. Fabry H, Yawalkar SJ. A comparative multicentre trial of halometasone ointment and fluocortolone plus fluocortolone caproate ointment in the treatment of psoriasis. J Int Med Res. 1983; 11 Suppl 1: 26–30.

143. Lee CS, Koo J. The efficacy of three class I topical synthetic corticosteroids, fluocinonide 0.1% cream, clobetasol 0.05% cream and halobetasol 0.05% cream: a Scholtz-Dumas bioassay comparison. J Drugs Dermatol. 2009; 8: 751–5.

144. Grupper C. The chemestry, pharmacology abd use of tar in treatment of psoriasis. In: Farber EM, Cox AJ: Psoriasis: Proceeding of International Symposium, 1971: 347–56.

145. Frost P, Horwitz SN, Caputo RV, Berger SM. Tar gel-phototherapy for psoriasis. Combined therapy with suberythemogenic doses of fluorescent sunlamp ultraviolet radiation. Arch Dermatol. 1979; 115: 840–6.

146. Andrys C, Borska L, Pohl D, Fiala Z, Hamakova K, Krejsek J. Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman’s therapy. Arch Dermatol Res. 2007; 298: 479–83.

147. Bagel J. LCD plus NB-UVB reduces time to improvement of psoriasis vs. NB-UVB alone. J Drugs Dermatol. 2009; 8: 351–7.

148. Belsito DV, Kechijian P. The role of tar in Goeckerman therapy. Arch Dermatol. 1982; 118: 319–21.

149. Diette KM, Momtaz K, Stern RS, Arndt KA, Parrish JA. Role of ultraviolet A in phototherapy for psoriasis. J Am Acad Dermatol. 1984; 11: 441–7.

150. LeVine MJ, Parrish JA. The effect of topical fluocinonide ointment on phototherapy of psoriasis. J Invest Dermatol. 1982; 78: 157–9.

151. Hauptverband der gewerblichen Berufsgenossenschaften e.V. Berufsgenossenschaftliche Grundsätze für arbeitsmedizinische Vorsorgeuntersuchungen bei Einwirkung krebserzeugener Arbeitsstoffe. Arbeitsmed, Sozialmed, Präventivmed. 1982; 17: 228–38.

152. Lee WR, Alderson MR, Downes JE. Scrotal cancer in the north-west of England, 1962-68. Br J Ind Med. 1972; 29: 188–95.

153. Diette KM, Momtaz TK, Stern RS, Arndt KA, Parrish JA. Psoralens and UV-A and UV-B twice weekly for the treatment of psoriasis. Arch Dermatol. 1984; 120: 1169–73.

154. Gollnick H, Menter A. Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis. Br J Dermatol. 1999; 140 Suppl 54: 18–23.

155. Weinstein GD, Koo JY, Krueger GG, Lebwohl MG, Lowe NJ, Menter MA, Lew-Kaya DA, Sefton J, Gibson JR, Walker PS. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol. 2003; 48: 760–7.

156. Green L, Sadoff W. A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. J Cutan Med Surg. 2002; 6: 95–102.

157. Koo JY, Martin D. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. Int J Dermatol. 2001; 40: 210–2.

158. Lebwohl M. Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. J Am Acad Dermatol. 2000; 43: S43–6.

159. Poulin YP. Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study. Cutis. 1999; 63: 41–8.

160. Veraldi S, Caputo R, Pacifico A, Peris K, Soda R, Chimenti S. Short contact therapy with tazarotene in psoriasis vulgaris. Dermatology. 2006; 212: 235–7.

161. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O’Garra A. 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol. 2001; 167: 4974–80.

162. Takeuchi A, Reddy GS, Kobayashi T, Okano T, Park J, Sharma S. Nuclear factor of activated T cells (NFAT) as a molecular target for 1alpha,25-dihydroxyvitamin D3-mediated effects. J Immunol. 1998; 160: 209–18.

163. Guenther L, Van de Kerkhof PC, Snellman E, Kragballe K, Chu AC, Tegner E, Garcia-Diez A, Springborg J. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol. 2002; 147: 316–23.

164. Kragballe K, Noerrelund KL, Lui H, Ortonne JP, Wozel G, Uurasmaa T, Fleming C, Estebaranz JL, Hanssen LI, Persson LM. Efficacy of oncedaily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol. 2004; 150: 1167–73.

165. Ortonne JP, Kaufmann R, Lecha M, Goodfield M. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology. 2004; 209: 308–13.

166. Guenther LC, Poulin YP, Pariser DM. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Clin Ther. 2000; 22: 1225–38.

167. Korver JE, Vissers WH, van Rens DW, Pasch MC, van Erp PE, Boezeman JB, van De Kerkhof PC. A double-blind, randomized quantitative comparison of calcitriol ointment and calcipotriol ointment on epidermal cell populations, proliferation and differentiation. Br J Dermatol. 2007; 156: 130–7.

168. Saraceno R, Andreassi L, Ayala F, Bongiorno MR, Giannetti A, Lisi P, Martini P, Peris K, Peserico A, Chimenti S. Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial. J Dermatolog Treat. 2007; 18: 361–5.

169. Zhu X, Wang B, Zhao G, Gu J, Chen Z, Briantais P, Andres P. An investigator-

masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 microg/g ointment vs. calcipotriol 50 microg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis. J Eur Acad Dermatol Venereol. 2007; 21: 466–72.

170. Austad J, Bjerke JR, Gjertsen BT, Helland S, Livden JK, Morken T, Mork NJ. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis. J Eur Acad Dermatol Venereol. 1998; 11: 19–24.

171. Perez A, Chen TC, Turner A, Raab R, Bhawan J, Poche P, Holick MF. Efficacy

and safety of topical calcitriol (1,25-dihydroxyvitamin d3) for the treatment of psoriasis. Br J Dermatol. 1996; 134: 238–46.

172. White S, Vender R, Thaci D, Haverkamp C, Naeyaert J-M, Foster R, Martinez Escribano JA, Cambazard F, Bibby A. Use of calcipotriene cream (Dovonex Cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex). Am J Clin Dermatol. 2006; 7: 177–84.

173. Abe M, Syuto T, Hasegawa M, Sogabe Y, Yokoyama Y, Ishikawa O. Daily versus intermittent application of high-concentration tacalcitol ointment in combination with low-dose cyclosporin for psoriasis vulgaris. J Dermatol. 2006; 33: 108–11.

174. Brazzelli V, Barbagallo T, Prestinari F, Rona C, De Silvestri A, Trevisan V, Borroni G. Non-invasive evaluation of tacalcitol plus ПУФА versus tacalcitol plus UVB-NB in the treatment of psoriasis: “right-left intra-individual pre/post comparison design”. Int J Immunopathol Pharmacol. 2005; 18: 755–60.

175. Cassano N, Miracapillo A, Coviello C, Loconsole F, Bellino M, Vena GA. Treatment of psoriasis vulgaris with the two-compound product calcipotriol/ betamethasone dipropionate followed by different formulations of calcipotriol. Clin Drug Investig. 2006; 26: 227–33.

176. Ezquerra GM, Regana MS, Millet PU. Combination of acitretin and oral calcitriol for treatment of plaquetype psoriasis. Acta Derm Venereol. 2007; 87: 449–50.

177. Abe M, Ishibuchi H, Syuto T, Sogabe Y, Yokoyama Y, Ishikawa O. Clinical usefulness and patient satisfaction for treatment with low-dose cyclosporin administration in patients with moderate psoriasis vulgaris. J Dermatol. 2007; 34: 290–3.

178. Erceg A, Bovenschen HJ, van de Kerkhof PC, Seyger MM. Efficacy of the pulsed dye laser in the treatment of localized recalcitrant plaque psoriasis: a comparative study. Br J Dermatol. 2006; 155: 110–4.

179. Lebwohl M, Yoles A, Lombardi K, Lou W. Calcipotriene ointment and halobetasol ointment in the longterm treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol. 1998; 39: 447–50.

180. Holzle E, Honigsmann H, Rocken M, Ghoreschi K, Lehmann P. [Recommendations for phototherapy and photochemotherapy]. J Dtsch Dermatol Ges. 2003; 1: 985–97.

181. Ramsay CA, Schwartz BE, Lowson D, Papp K, Bolduc A, Gilbert M. Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVBsparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group. Dermatology. 2000; 200: 17–24.

182. Brockow T, Schiener R, Franke A, Resch KL, Peter RU. A pragmatic randomized controlled trial on the effectiveness of highly concentrated saline spa water baths followed by UVB compared to UVB only in moderate to severe psoriasis. J Altern Complement Med. 2007; 13: 725–32.

183. Brockow T, Schiener R, Franke A, Resch KL, Peter RU. A pragmatic randomized controlled trial on the effectiveness of low concentrated saline spa water baths followed by ultraviolet B (UVB) compared to UVB only in moderate to severe psoriasis. J Eur Acad Dermatol Venereol. 2007; 21: 1027-37.

184. De Leeuw J, Van Lingen RG, Both H, Tank B, Nijsten T, Martino Neumann HA. A comparative study on the efficacy of treatment with 585 nm pulsed dye laser and ultraviolet BTL01 in plaque type psoriasis. Dermatol Surg. 2009; 35: 80–91.

185. Ring J, Kowalzick L, Christophers E, Schill WB, Schopf E, Stander M, Wolff HH, Altmeyer P. Calcitriol 3 microg g-1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: results of a comparative study. Br J Dermatol. 2001; 144: 495–9.

186. Youssef RM, Mahgoub D, Mashaly HM, El-Nabarawy E, Samir N, El-Mofty M. Different narrowband UVB dosage regimens in dark skinned psoriatics: a preliminary study. Photodermatol Photoimmunol Photomed. 2008; 24: 256–9.

187. Petrozzi JW. Topical steroids and UV radiation in psoriasis. Arch Dermatol. 1983; 119: 207–10.

188. Serwin AB, Wasowicz W, Chodynicka B. Selenium supplementation, soluble tumor necrosis factor-alpha receptor type 1, and C-reactive protein during psoriasis therapy with narrowband ultraviolet B. Nutrition. 2006; 22: 860–4.

189. Coven TR, Burack LH, Gilleaudeau R, Keogh M, Ozawa M, Krueger JG. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol. 1997; 133: 1514–22.

190. Snellman E, Klimenko T, Rantanen T. Randomized half-side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. Acta Derm Venereol. 2004; 84: 132–7.

191. Amornpinyokeit N, Asawanonda P. 8-Methoxypsoralen cream plus targeted narrowband ultraviolet B for psoriasis. Photodermatol Photoimmunol Photomed. 2006; 22: 285–9.

192. Gordon PM, Diffey BL, Mattews JNS, Farr PM. A randomised comparison of narrow-band TL-01 phototherapy and ПУФА photochemotherapy for psoriasis. J Am Acad Dermatol. 1999; 41: 728–32.

193. Leenutaphong V, Nimkulrat P, Sudtim S. Comparison of phototherapy two times and four times a week with low doses of narrow-band ultraviolet B in Asian patients with psoriasis. Photodermatol Photoimmunol Photomed. 2000; 16: 202–6.

194. Yones SS, Palmer RA, Garibaldinos TT, Hawk JL. Randomized doubleblind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol. 2006; 142: 836–42.

195. Goldinger SM, Dummer R, Schmid P, Prinz Vavricka M, Burg G, Lauchli S. Excimer laser versus narrow-band UVB (311 nm) in the treatment of psoriasis vulgaris. Dermatology. 2006; 213: 134–9.

196. Kaur M, Oliver B, Hu J, Feldman SR. Nonlaser UVB-targeted phototherapy treatment of psoriasis. Cutis. 2006; 78: 200–3.

197. Grundmann-Kollmann M, Ludwig R, Zollner TM, Ochsendorf F, Thaci D, Boehncke WH, Krutmann J, Kaufmann R, Podda M. Narrowband UVB and cream psoralen-UVA combination therapy for plaque-type psoriasis. J Am Acad Dermatol. 2004; 50: 734–9.

198. Parrish JA, Fitzpatrick TB, Tanenbaum L, Pathak MA. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med. 1974; 291: 1207–11.

199. Housman TS, Pearce DJ, Feldman SR. A maintenance protocol for psoriasis plaques cleared by the 308 nm excimer laser. J Dermatolog Treat. 2004; 15: 94–7.

200. Katugampola GA, Rees AM, Lanigan SW. Laser treatment of psoriasis. Br J Dermatol. 1995; 133: 909–13.

201. Trehan M, Taylor CR. Medium-dose 308-nm excimer laser for the treatment of psoriasis. J Am Acad Dermatol. 2002; 47: 701–8.

202. Feldman SR, Mellen BG, Housman TS, Fitzpatrick RE, Geronemus RG, Friedman PM, Vasily DB, Morison WL. Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study. J Am Acad Dermatol. 2002; 46: 900–6.

203. Arnold WP, van Andel P, de Hoop D, de Jong-Tieben L, Visser-van Andel M. A comparison of the effect of narrow-band ultraviolet B in the treatment of psoriasis after salt-water baths and after 8-methoxypsoralen baths. Br J Dermatol. 2001; 145:

352–4.

204. Schiener R, Brockow T, Franke A, Salzer B, Peter RU, Resch KL. Bath ПУФА and saltwater baths followed by UV-B phototherapy as treatments for psoriasis: a randomized controlled trial. Arch Dermatol. 2007; 143: 586–96.

206. Buckley DA, Healy E, Rogers S. A comparison of twice-weekly MPDПУФА and three times-weekly skin typing-ПУФА regimens for the treatment of psoriasis. Br J Dermatol. 1995; 133: 417–22.

207. Berg M, Ros AM. Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen. Photodermatol Photoimmunol Photomed. 1994; 10: 217–20.

208. Cooper EJ, Herd RM, Priestley GC, Hunter JA. A comparison of bathwater and oral delivery of 8-methoxypsoralen in ПУФА therapy for plaque psoriasis. Clin Exp Dermatol. 2000; 25: 111–4.

209. Collins P, Rogers S. Bath-water compared with oral delivery of 8-methoxypsoralen ПУФА therapy for chronic plaque psoriasis. Br J Dermatol. 1992; 127: 392–5.

210. Calzavara-Pinton PG, Ortel B, Honigsmann H, Zane C, De Panfilis G. Safety and effectiveness of an aggressive and individualized bath-ПУФА regimen in the treatment of psoriasis. Dermatology. 1994; 189: 256–9.

211. Vongthongsri R, Konschitzky R, Seeber A, Treitl C, Honigsmann H, Tanew A. Randomized, double-blind comparison of 1 mg/L versus 5 mg/L methoxsalen bath-ПУФА therapy for chronic plaque-type psoriasis. J Am Acad Dermatol. 2006; 55: 627–31.

212. Barth J, Dietz O, Heilmann S, Kadner H, Kraensel H, Meffert H, Metz D, Pinzer B, Schiller F. [Photochemotherapy by 8-methoxypsoralen and UVA in psoriasis vulgaris—clinical experiences in 5 dermatological departments of GDR (author’s transl)]. Dermatol Monatsschr. 1978; 164: 401–7.

213. Asawanonda P, Amornpinyokeit N, Nimnuan C. Topical 8-methoxypsoralen enhances the therapeutic results of targeted narrowband ultraviolet B phototherapy for plaque-type psoriasis. J Eur Acad Dermatol Venereol. 2008; 22: 50–5.

214. Khurshid K, Haroon TS, Hussain I, Pal SS, Jahangir M, Zaman T. Psoralen-ultraviolet A therapy vs. Psoralenultraviolet B therapy in the treatment of plaque-type psoriasis: our experience with fitzpatrick skin type IV. Int J Dermatol. 2000; 39: 865–7.

215. Park YK, Kim HJ, Koh YJ. Combination of photochemotherapy (ПУФА) and ultraviolet B (UVB) in the treatment of psoriasis vulgaris. J Dermatol. 1988; 15: 68–71.

216. Kabat-Zinn J, Wheeler E, Light T, Skillings A, Scharf MJ, Cropley TG, Hosmer D, Bernhard JD. Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (ПУФА). Psychosom Med. 1998; 60: 625–32.

217. Robertson DB, McCarty JR, Jarratt M. Treatment of psoriasis with 8-methoxypsoralen and sunlight. South Med J. 1978; 71: 1345–9.

218. Fleischer AB, Jr., Clark AR, Rapp SR, Reboussin DM, Feldman SR. Commercial tanning bed treatment is an effective psoriasis treatment: results from an uncontrolled clinical trial. J Invest Dermatol. 1997; 109: 170–4.

219. Frappaz A, Thivolet J. Calcipotriol in combination with ПУФА: A randomized double blind placebo study in severe psoriasis. Eur J Dermatol. 1993; 3: 351–54.

220. Dover JS, McEvoy MT, Rosen CF, Arndt KA, Stern RS. Are topical corticosteroids useful in phototherapy for psoriasis? J Am Acad Dermatol. 1989; 20: 748–54.

221. Hanke CW, Steck WD, Roenigk HH, Jr. Combination therapy for psoriasis. Psoralens plus long-wave ultraviolet radiation with betamethasone valerate. Arch Dermatol. 1979; 115: 1074–7.

222. Koo JY, Lowe NJ, Lew-Kaya DA, Vasilopoulos AI, Lue JC, Sefton J, Gibson JR. Tazarotene plus UVB phototherapy in the treatment of psoriasis. J Am Acad Dermatol. 2000; 43: 821–8.

223. McBride SR, Walker P, Reynolds NJ. Optimizing the frequency of outpatient short-contact dithranol treatment used in combination with broadband ultraviolet B for psoriasis: a randomized, within-patient controlled trial. Br J Dermatol. 2003; 149: 1259–65.

224. Vella Briffa D, Rogers S, Greaves MW, Marks J, Shuster S, Warin AP. A randomized, controlled clinical trial comparing photochemotherapy with dithranol in the initial treatment of chronic plaque psoriasis. Clin Exp Dermatol. 1978; 3: 339–47.

225. Rogers S, Marks J, Shuster S, Briffa DV, Warin A, Greaves M. Comparison of photochemotherapy and dithranol in the treatment of chronic plaque psoriasis. Lancet. 1979; 1: 455–8.

226. Parker S, Coburn P, Lawrence C, Marks J, Shuster S. A randomized double-blind comparison of ПУФА etretinate and ПУФА-placebo in the treatment of chronic plaque psoriasis. Br J Dermatol. 1984; 110: 215–20.

227. Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, Heffernan M, Miller B, Hamlin R, Lim L, Zhong J, Hoffman R, Okun MM. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: doubleblind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006; 55: 598–606.

228. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008; 58: 106–15.

229. Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, Camez A. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2008; 158: 549–57.

230. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink K, Kaul M, Camez A. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008; 158: 558–66.

231. Bongiorno MR, Pistone G, Doukaki S, Arico M. Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis. Dermatol Ther. 2008; 21 Suppl 2: S15–20.

232. Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, Bianchi L, Chimenti S. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol. 2007; 57: 269–75.

233. van Lingen RG, de Jong EM, Berends MA, Seyger MM, van Erp PE, van de Kerkhof PC. Good clinical response to anti-psoriatic treatment with adalimumab and methotrexate does not inflict a direct effect on compartmentalization of T-cell subsets: a pilot study. J Dermatolog Treat. 2008; 19: 284–7.

234. Vena GA, Galluccio A, De Simone C, Mastrandrea V, Buquicchio R, La Greca S, Dattola S, Puglisi Guerra A, Donato L, Cantoresi F, De Pita O, Pezza M, M DA, Vernaci R, Miracapillo A, Valenti G, Cassano N. A multicenter open-label experience on the response of psoriasis to Adalimumab and effect of dose escalation in non-responders: the Aphrodite project. Int J Immunopathol Pharmacol. 2009; 22: 227–33.

235. Diel R, Hauer B, Loddenkemper R, Manger B, Kruger K. [Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases]. Z Rheumatol. 2009; 68: 411–6.

236. Muller W, Herrmann B. [Influence of cyclosporin A on psoriasis]. Dtsch Med Wochenschr. 1979; 104: 1047.

237. Koo J. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. Br J Dermatol. 1998; 139: 88–95.

238. Sterry W, Barker J, Boehncke WH, Bos JD, Chimenti S, Christophers E, De La Brassinne M, Ferrandiz C, Griffiths C, Katsambas A, Kragballe K, Lynde C, Menter A, Ortonne JP, Papp K, Prinz J, Rzany B, Ronnevig J, Saurat JH, Stahle M, Stengel FM, Van De Kerkhof P, Voorhees J. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol. 2004; 151 Suppl 69: 3–17.

239. Mrowietz U. Ciclosporin in der Dermatologie. Georg Thieme Verlag, Stuttgart, 2003.

240. Powles AV, Baker BS, McFadden J, Rutman AJ, Griffiths CE, Fry L, Valdimarsson H. Intralesional injection of cyclosporin in psoriasis. Lancet. 1988; 1: 537.

241. Powles AV, Baker BS, McFadden JP, Valdimarsson H, Fry L. Intralesional cyclosporin in psoriasis. Acta Derm Venereol Suppl (Stockh). 1989; 146: 148–9; discussion 49–50.

242. Wong RL, Winslow CM, Cooper KD. The mechanisms of action of cyclosporin A in the treatment of psoriasis. Immunol Today. 1993; 14: 69–74.

243. Thaci D, Brautigam M, Kaufmann R, Weidinger G, Paul C, Christophers E. Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study. Dermatology. 2002; 205: 383–8.

244. Hashizume H, Ito T, Yagi H, Takigawa M, Kageyama H, Furukawa F, Hata M, Shirahama S, Tanaka M, Higashishiba T, Machida H, Tsushima T, Matsushita K. Efficacy and safety of preprandial versus postprandial administration of low-dose cyclosporin microemulsion (Neoral) in patients with psoriasis vulgaris. J Dermatol. 2007; 34: 430–4.

245. Yoon HS, Youn JI. A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis. J Dermatolog Treat. 2007; 18: 286–90.

246. Ho VC, Griffiths CE, Berth-Jones J, Papp KA, Vanaclocha F, Dauden E, Beard A, ПУФАnarajan L, Paul C. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol. 2001; 44: 643–51.

247. Mahrle G, Schulze HJ, Farber L, Weidinger G, Steigleder GK. Lowdose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol. 1995; 32: 78–88.

248. Nakayama J, Hori Y, Nakagawa H, Ishibashi Y, Horikoshi T, Ozawa A, Sugai J, Ohkido M. Comparison of two therapeutic regimens, continous monotherapy and intermittent therapy, for long-term maintenance of remission of psoriasis with cyclosporin A. Eur J Dermatol. 1996; 6: 341–43.

249. Chaidemenos GC, Mourellou O, Avgoustinaki N, Papakonstantinou M, Karakatsanis G, Katsambas A. Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2007; 21: 1203–8.

250. Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH, Rocher LL, Wheeler S, Hamilton TA, Parish TG, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med. 1991; 324: 277–84.

251. Elder CA, Moore M, Chang CT, Jin J, Charnick S, Nedelman J, Cohen A, Guzzo C, Lowe N, Simpson K, et al. Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis. J Clin Pharmacol. 1995; 35: 865–75.

252. Engst R, Huber J. [Results of cyclosporin treatment of severe, chronic psoriasis vulgaris]. Hautarzt. 1989; 40: 486–9.

253. Finzi AF, Mozzanica N, Pigatto PD, Cattaneo A, Ippolito F. Cyclosporine versus etretinate: Italian multicentre comparative trial in severe psoriasis. Dermatology. 1993; 187: 8–18.

254. Flytstrom I, Stenberg B, Svensson A, Bergbrant IM. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol. 2008; 158: 116–21.

255. Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigatorblinded clinical trial. Am J Clin Nutr. 2008; 88: 1242–7.

256. Heydendael VM, Spuls PI, Opmeer BC, de Borgie CA, Reitsma JB, Goldschmidt WF, Bossuyt PM, Bos JD, de Rie MA. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med. 2003; 349: 658–65.

257. Laburte C, Grossman R, Abi-Rached J, Abeywickrama KH, Dubertret L. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol. 1994; 130: 366–75.

258. Levell NJ, Shuster S, Munro CS, Friedmann PS. Remission of ordinary psoriasis following a short clearance course of cyclosporin. Acta Derm Venereol. 1995; 75: 65–9.

259. Meffert H, Brautigam M, Farber L, Weidinger G. Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile. Acta Derm Venereol. 1997; 77: 137–41.

260. Reitamo S, Spuls P, Sassolas B, Lahfa M, Claudy A, Griffiths CE. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol. 2001; 145: 438–45.

261. Finzi AF, Mozzanica N, Cattaneo A, Chiappino G, Pigatto PD. Effectiveness of cyclosporine treatment in severe psoriasis: a clinical and immunologic study. J Am Acad Dermatol. 1989; 21: 91–7.

262. Grossman RM, Thivolet J, Claudy A, Souteyrand P, Guilhou JJ, Thomas P, Amblard P, Belaich S, de Belilovsky C, de la Brassinne M, et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol.

1994; 31: 68–74.

263. Higgins E, Munro C, Marks J, Friedmann PS, Shuster S. Relapse rates in moderately severe chronic psoriasis treated with cyclosporin A. Br J Dermatol. 1989; 121: 71–4.

264. Lago E, Carneiro S, Cuzzi T, Magalhaes G, Cassia F, Pessanha F, Ramose-Silva M. Clinical and immunohistochemical assessment of the effect of cyclosporin in keratinocytes and dermal dendrocytes in psoriasis. J Cutan Pathol. 2007; 34: 15–21.

265. Ohtsuka T. The correlation between response to oral cyclosporin therapy and systemic inflammation, metabolic abnormality in patients with psoriasis. Arch Dermatol Res. 2008; 300: 545–50.

266. Stinco G, Lautieri S, Valent F, Patrone P. Cutaneous vascular alterations in psoriatic patients treated with cyclosporine. Acta Derm Venereol. 2007; 87: 152–4.

267. Petzelbauer P, Honigsmann H, Langer K, Anegg B, Strohal R, Tanew A, Wolff K. Cyclosporin A in combination with photochemotherapy (ПУФА) in the treatment of psoriasis. Br J Dermatol. 1990; 123: 641–7.

268. Franchi C, Cainelli G, Frigerio E, Garutti C, Altomare GF. Association of cyclosporine and 311 nM UVB in the treatment of moderate to severe forms of psoriasis: a new strategic approach. Int J Immunopathol Pharmacol. 2004; 17: 401–6.

269. Vena GA, Cassano N, Loconsole F, Malara G, Sciarrone C, Puglisi Guerra A. Sequential treatment of psoriasis with infliximab followed by cyclosporin. Preliminary results of an open-label prospective study. G Ital Dermatol Venereol. 2006; 141: 221–5.

270. Ameen M, Smith HR, Barker JN. Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis. Clin Exp Dermatol. 2001; 26: 480–3.

271. Balasubramaniam P, Stevenson O, Berth-Jones J. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities. Br J Dermatol. 2004; 150: 741–6.

272. Clark CM, Kirby B, Morris AD, Davison S, Zaki I, Emerson R, Saihan EM, Chalmers RJ, Barker JN, Allen BR, Griffiths CE. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol. 1999; 141: 279–82.

273. Kokelj F, Torsello P, Plozzer C. Calcipotriol improves the efficacy of cyclosporine in the treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 1998; 10: 143–6.

274. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given ПУФА and ciclosporin: nested cohort crossover study. Lancet. 2001; 358: 1042–5.

275. Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, Lamarque V, Dubertret L. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol. 2003; 120: 211–6.

276. Agnew KL, Bunker CB. Multiple cutaneous squamous carcinoma in a psoriatic associated with ciclosporin, alcohol abuse and ultraviolet radiation exposure which were suppressed by acitretin. J Eur Acad Dermatol Venereol. 2003; 17: 113–4.

277. van de Kerkhof PC, Cambazard F, Hutchinson PE, Haneke E, Wong E, Souteyrand P, Damstra RJ, Combemale P, Neumann MH, Chalmers RJ, Olsen L, Revuz J. The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis. Br J Dermatol. 1998; 138: 84–9.

278. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol. 1994; 96: 146–51.

279. Mussi A, Bonifati C, Carducci M, D’Agosto G, Pimpinelli F, D’Urso D, D’Auria L, Fazio M, Ameglio F. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents. 1997; 11: 115–8.

280. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Tsuji W. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004; 50: 2264–72.

281. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, McDonnell ND, Weinblatt ME. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999; 130: 478–86.

282. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, Gordon KB, Zitnik R. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003; 139: 1627–32; discussion 32.

283. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003; 349: 2014–22.

284. Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005; 152: 1304–12.

285. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebocontrolled randomised phase III trial. Lancet. 2006; 367: 29–35.

286. van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with

open-label extension. Br J Dermatol. 2008; 159: 1177–85.

287. Berends MA, Driessen RJ, Langewouters AM, Boezeman JB, Van De Kerkhof PC, De Jong EM. Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice. J Dermatolog Treat. 2007; 18: 76–83.

288. Caproni M, Antiga E, Melani L, Volpi W, Del Bianco E, Fabbri P. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol. 2009; 29: 210–4.

289. Cassano N, Loconsole F, Galluccio A, Miracapillo A, Pezza M, Vena GA. Once-weekly administration of highdosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study). Int J Immunopathol Pharmacol. 2006; 19: 225–9.

290. Gisondi P, Del Giglio M, Cotena C, Girolomoni G. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigatorblinded pilot trial. Br J Dermatol. 2008; 158: 1345–9.

291. Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, Stevens SR. A randomized, openlabel trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007; 56: 598–603.

292. van Lingen RG, Korver JE, van de Kerkhof PC, Berends MA, van Rens DW, Langewouters AM, Boezeman JB, Seyger MM, de Jong EM. Relevance of compartmentalization of T-cell subsets for clinical improvement in psoriasis: effect of immunetargeted antipsoriatic therapies. Br J Dermatol. 2008; 159: 91–6.

293. Campanati A, Goteri G, Simonetti O, Ganzetti G, Giuliodori K, Giuliano A, Sabato S, Stramazzotti D, Gulini E, Dusi D, De Blasio S, Fabris G, Offidani A. Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation. Int J Immunopathol Pharmacol. 2009; 22: 371–7.

294. Costanzo A, Mazzotta A, Papoutsaki M, Nistico S, Chimenti S. Safety and efficacy study on etanercept in patients with plaque psoriasis. Br J Dermatol. 2005; 152: 187–9.

295. Koc E, Tunca M, Akgul EO, Akar A, Kurt Y, Kurumlu Z, Erbil K, Kilic S. Effects of etanercept on urine neopterin levels in patients with psoriasis in a controlled, open-label study. J Dermatol. 2009; 36: 191–6.

296. Kircik L, Bagel J, Korman N, Menter A, Elmets CA, Koo J, Yang YC, Chiou CF, Dann F, Stevens SR. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. J Drugs Dermatol. 2008; 7: 245–53.

297. Zachariae C, Mork NJ, Reunala T, Lorentzen H, Falk E, Karvonen SL, Johannesson A, Clareus B, Skov L, Mork G, Walker S, Qvitzau S. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol. 2008; 88: 495–501.

298. Klareskog L, Moreland LM, Bohen SB. Global safety and efficacy of up to five years of etanercept (Enbrel) therapy. Arthritis Rheum. 2001; 44.

299. Moreland LW, Cohen SB, Baumgartner SW. Etanercept (Enbrel) monotherapy for more than 5 years in patients with DMARD-refrectory rheumatoid arthritis. Arthritis Rheum. 2002; 46: 533.

300. Holman J, Wallis WJ, Sabath DF. Tuberculosis reports with etanercept (Enbrel) therapy. Ann Dis Rheum. 2002; 61.

301. Fachinformation Wyeth. Aktuelle Version.

302. Lebwohl M, Gottlieb A, Wallis WJ, et al. Safety and efficacy of over 7 years of etanercept therapy in a global population of patients with rheumatoid arthritis. J Am Acad Dermatol. 2005; 52: 2792.

303. Mrowietz U, Asadullah K. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Med. 2005; 11: 43–8.

304. Vandermeeren M, Janssens S, Borgers M, Geysen J. Dimethylfumarate is an inhibitor of cytokine-induced Eselectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem Biophys Res Commun. 1997; 234: 19–23.

305. Litjens NH, Nibbering PH, Barrois AJ, Zomerdijk TP, Van Den Oudenrijn AC, Noz KC, Rademaker M, Van De Meide PH, Van Dissel JT, Thio B. Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines. Br J Dermatol. 2003; 148: 444–51.

306. Zhu K, Mrowietz U. Inhibition of dendritic cell differentiation by fumaric acid esters. J Invest Dermatol. 2001; 116: 203–8.

307. Asadullah K, Schmid H, Friedrich M, Randow F, Volk HD, Sterry W, Docke WD. Influence of monomethylfumarate on monocytic cytokine formation—explanation for adverse and therapeutic effects in psoriasis? Arch Dermatol Res. 1997; 289: 623–30.

308. de Jong R, Bezemer AC, Zomerdijk TP, van de Pouw-Kraan T, Ottenhoff TH, Nibbering PH. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol. 1996; 26: 2067–74.

309. Ockenfels HM, Schultewolter T, Ockenfels G, Funk R, Goos M. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol. 1998; 139: 390–5.

310. Treumer F, Zhu K, Glaser R, Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol. 2003; 121: 1383–8.

311. Altmeyer PJ, Matthes U, Pawlak F, Hoffmann K, Frosch PJ, Ruppert P, Wassilew SW, Horn T, Kreysel HW, Lutz G, et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol. 1994; 30: 977–81.

312. Gollnick H, Altmeyer P, Kaufmann R, Ring J, Christophers E, Pavel S, Ziegler J. Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris. Dermatology. 2002; 205: 46–53.

313. Kolbach DN, Nieboer C. Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment. J Am Acad Dermatol. 1992; 27: 769–71.

314. Nugteren-Huying WM, van der Schroeff JG, Hermans J, Suurmond D. [Fumaric acid therapy in psoriasis; a double-blind, placebo-controlled study]. Ned Tijdschr Geneeskd. 1990; 134: 2387–91.

315. Altmeyer P, Hartwig R, Matthes U. [Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients]. Hautarzt. 1996; 47: 190–6.

316. Bayard W, Hunziker T, Krebs A, Speiser P, Joshi R. [Peroral long-term treatment of psoriasis using fumaric acid derivatives]. Hautarzt. 1987; 38: 279–85.

317. Carboni I, De Felice C, De Simoni I, Soda R, Chimenti S. Fumaric acid esters in the treatment of psoriasis: an Italian experience. J Dermatolog Treat. 2004; 15: 23–6.

318. Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br J Dermatol. 1998; 138: 456–60.

319. Nieboer C, de Hoop D, van Loenen AC, Langendijk PN, van Dijk E. Systemic therapy with fumaric acid derivates: new possibilities in the treatment of psoriasis. J Am Acad Dermatol. 1989; 20: 601–8.

320. Hoefnagel JJ, Thio HB, Willemze R, Bouwes Bavinck JN. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol. 2003; 149: 363–9.

321. Reich K, Thaci D, Mrowietz U, Kamps A, Neureither M, Luger T. Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis—a retrospective study (FUTURE). J Dtsch Dermatol Ges. 2009; 7: 603–11.

322. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005; 64: 1150–7.

323. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, Bala M, Marano CW, Menter A. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol.

2004; 51: 534–42.

324. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005; 366: 1367–74.

325. Reich K, Nestle FO, Wu Y, Bala M, Eisenberg D, Guzzo C, Li S, Dooley LT, Griffiths CE. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Eur J Dermatol. 2007; 17: 381–6.

326. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001; 357: 1842–7.

327. Cassano N, Puglisi Guerra A, Malara C, Loconsole F, Galluccio A, Pezza M, Vena GA. Re-induction as a possible alternative modality of dose escalation of infliximab: a prospective evaluation in a small series of psoriatic patients. Int J Immunopathol Pharmacol. 2007; 20: 647–50.

328. Lemme G, Campanati A, Paolinelli M, Offidani A. Diffuse psoriasis plaque type and infliximab: our experience and review of literature. G Ital Dermatol Venereol. 2007; 142: 9–14.

329. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol. 2002; 46: 886–91.

330. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007; 56: 31 e1–15.

331. Augustsson J, Eksborg S, Ernestam S, Gullstrom E, van Vollenhoven R. Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2007; 66: 1462–6.

332. Lecluse LL, Piskin G, Mekkes JR, Bos JD, de Rie MA. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol. 2008; 159: 527–36.

333. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999; 354: 1932–9.

334. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat. 2004; 15: 280–94.

335. Bianchi L, Bergamin A, de Felice C, Capriotti E, Chimenti S. Remission and time of resolution of nail psoriasis during infliximab therapy. J Am Acad Dermatol. 2005; 52: 736–7.

336. Rich P, Griffiths CE, Reich K, Nestle FO, Scher RK, Li S, Xu S, Hsu MC, Guzzo C. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol. 2008; 58: 224–31.

337. Rigopoulos D, Gregoriou S, Stratigos A, Larios G, Korfitis C, Papaioannou D, Antoniou C, Ioannides D. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Br J Dermatol. 2008; 159: 453–6.

338. Fachinformation essex pharma. Aktuelle Version.

339. Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci. 1951; 221: 176–82.

340. Smith KC. Systemic therapy of psoriasis using methotrexate. Skin Therapy Lett. 2000; 6: 1–2; 5.

341. Weinstein GD, Frost P. Methotrexate for psoriasis. A new therapeutic schedule. Arch Dermatol. 1971; 103: 33–8.

342. Roenigk HH, Jr., Auerbach R, Maibach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol. 1998; 38: 478–85.

343. van Dooren-Greebe RJ, Kuijpers AL, Termorshuizen F, van de Kerkhof PC. Interruption of long-term methotrexate treatment in psoriasis. Evaluation of clinical course and laboratory parameters after discontinuation and reintroduction of weekly oral methotrexate. Acta Derm Venereol. 1995; 75: 393–6.

344. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate

therapy for psoriasis. J Am Acad Dermatol. 1993; 28: 466–9.

345. Ortiz Z, Shea B, Suarez Almazor M, Moher D, Wells G, Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2000: CD000951.

346. van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, Westgeest TA, Romme TC, de Rooij DJ, Jacobs MJ, de Boo TM, van der Wilt GJ, Severens JL, Hartman M, Krabbe PF, Dijkmans BA, Breedveld FC, van de Putte LB. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebocontrolled study. Arthritis Rheum. 2001; 44: 1515–24.

347. Salim A, Tan E, Ilchyshyn A, Berth-Jones J. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, doubleblind, Dermatol. 2006; 154: 1169–74.

348. Chladek J, Simkova M, Vaneckova J, Hroch M, Chladkova J, Martinkova J, Vavrova J, Beranek M. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur J Clin Pharmacol. 2008; 64: 347–55.

349. Ranjan N, Sharma NL, Shanker V, Mahajan VK, Tegta GR. Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly dose to treat moderate-to-severe chronic plaque psoriasis: a comparative study. J Dermatolog Treat. 2007; 18: 295–300.

350. Hroch M, Chladek J, Simkova M, Vaneckova J, Grim J, Martinkova J. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. J Eur Acad Dermatol Venereol. 2008; 22: 19–24.

351. Nyfors A, Brodthagen H. Methotrexate for psoriasis in weekly oral doses without any adjunctive therapy. Dermatologica. 1970; 140: 345–55.

352. Asawanonda P, Nateetongrungsak Y. Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study. J Am Acad Dermatol. 2006; 54: 1013–8.

353. Paul BS, Momtaz K, Stern RS, Arndt KA, Parrish JA. Combined methotrexate

– ultraviolet B therapy in the treatment of psoriasis. J Am Acad Dermatol. 1982; 7: 758–62.

354. Morison WL, Momtaz K, Parrish JA, Fitzpatrick TB. Combined methotrexate-

ПУФА therapy in the treatment of psoriasis. J Am Acad Dermatol. 1982; 6: 46–51.

355. Van Dooren-Greebe RJ, Kuijpers AL, Mulder J, De Boo T, Van de Kerkhof PC. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol. 1994; 130: 204–10.

356. Nyfors A. Benefits and adverse drug experiences during long-term methotrexate

treatment of 248 psoriatics. Dan Med Bull. 1978; 25: 208–11.

357. Newman M, Auerbach R, Feiner H, Holzman RS, Shupack J, Migdal P, Culubret M, Camuto P, Tobias H. The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment. Improvement in liver abnormalities after cessation of treatment. Arch Dermatol. 1989; 125: 1218–24.

358. Whiting-O’Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med. 1991; 90: 711–6.

359. Menter MA, See JA, Amend WJ, Ellis CN, Krueger GG, Lebwohl M, Morison WL, Prystowsky JH, Roenigk HH, Jr., Shupack JL, Silverman AK, Weinstein GD, Yocum DE, Zanolli MD. Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994. J Am Acad Dermatol. 1996; 34: 315–21.

360. Said S, Jeffes EW, Weinstein GD. Methotrexate. Clin Dermatol. 1997; 15: 781–97.

361. Boffa MJ, Chalmers RJ, Haboubi NY, Shomaf M, Mitchell DM. Sequential liver biopsies during longterm methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol. 1995; 133: 774–8.

362. Malatjalian DA, Ross JB, Williams CN, Colwell SJ, Eastwood BJ. Methotrexate

hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term followup. Can J Gastroenterol. 1996; 10: 369–75.

363. Nyfors A. Liver biopsies from psoriatics related to methotrexate therapy. 3. Findings in post-methotrexate liver biopsies from 160 psoriatics. Acta Pathol Microbiol Scand A. 1977; 85: 511–8.

364. Robinson JK, Baughman RD, Auerbach R, Cimis RJ. Methotrexate hepatotoxicity in psoriasis. Consideration of liver biopsies at regular intervals. Arch Dermatol. 1980; 116: 413–5.

365. Warin AP, Landells JW, Levene GM, Baker H. A prospective study of the effects of weekly oral methotrexate on liver biopsy. Br J Dermatol. 1975; 93:

321–7.

367. Zachariae H, Kragballe K, Sogaard H. Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment. Br J Dermatol. 1980; 102: 407–12.

368. Nyfors A, Jensen H. Frequency of malignant neoplasms in 248 longterm methotrexate-treated psoriatics. A preliminary study. Dermatologica. 1983; 167: 260–1.

369. Rustin GJ, Newlands ES, Lutz JM, Holden L, Bagshawe KD, Hiscox JG, Foskett M, Fuller S, Short D. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol. 1996; 14: 2769–73.

370. Moy RL, Kingston TP, Lowe NJ. Isotretinoin vs etretinate therapy in generalized pustular and chronic psoriasis. Arch Dermatol. 1985; 121: 1297–301.

371. Gollnick H, Bauer R, Brindley C, Orfanos CE, Plewig G, Wokalek H, Hoting E. Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study. J Am Acad Dermatol. 1988; 19: 458–68.

372. Kragballe K, Jansen CT, Geiger JM, Bjerke JR, Falk ES, Gip L, Hjorth N, Lauharanta J, Mork NJ, Reunala T, et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study. Acta Derm Venereol. 1989; 69: 35–40.

373. Ledo A, Martin M, Geiger JM, Marron JM. Acitretin (Ro 10-1670) in the treatment of severe psoriasis. A randomized double-blind parallel study comparing acitretin and etretinate. Int J Dermatol. 1988; 27: 656–60.

374. Meffert H, Sonnichsen N. Acitretin in the treatment of severe psoriasis: a randomized double-blind study comparing acitretin and etretinate. Acta Derm Venereol Suppl (Stockh). 1989; 146: 176–7.

375. Goldfarb MT, Ellis CN, Gupta AK, Tincoff T, Hamilton TA, Voorhees JJ. Acitretin improves psoriasis in a dosedependent fashion. J Am Acad Dermatol. 1988; 18: 655–62.

376. Elias KM, Laurence A, Davidson TS, Stephens G, Kanno Y, Shevach EM, O’Shea JJ. Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. Blood. 2008; 111: 1013–20.

377. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, Cheroutre H. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science. 2007; 317: 256–60.

378. Sabat R, Wallace E, Endesfelder S, Wolk K. IL-19 and IL-20: two novel cytokines with importance in inflammatory diseases. Expert Opin Ther Targets. 2007; 11: 601–12.

379. Gollnick HP, Dummler U. Retinoids. Clin Dermatol. 1997; 15: 799–810.

380. Caca-Biljanovska NG, V’Lckova-Laskoska MT. Management of guttate and generalized psoriasis vulgaris: prospective randomized study. Croat Med J. 2002; 43: 707–12.

381. Gupta AK, Goldfarb MT, Ellis CN, Voorhees JJ. Side-effect profile of acitretin therapy in psoriasis. J Am Acad Dermatol. 1989; 20: 1088–93.

382. Mittal R, Malhotra S, Pandhi P, Kaur I, Dogra S. Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, doubleblind, placebo-controlled clinical

trial. Arch Dermatol. 2009; 145: 387–93.

383. Saurat JH, Geiger JM, Amblard P, Beani JC, Boulanger A, Claudy A, Frenk E, Guilhou JJ, Grosshans E, Merot Y, et al. Randomized doubleblind multicenter study comparing acitretin-ПУФА, etretinate-ПУФА and placebo-ПУФА in the treatment of severe psoriasis. Dermatologica. 1988; 177: 218–24.

384. Lauharanta J, Geiger JM. A doubleblind comparison of acitretin and etretinate in combination with bath ПУФА in the treatment of extensive psoriasis. Br J Dermatol. 1989; 121: 107–12.

385. Ozdemir M, Engin B, Baysal I, Mevlitoglu I. A randomized comparison of acitretin-narrow-band TL-01 phototherapy and acitretinpsoralen plus ultraviolet A for psoriasis. Acta Derm Venereol. 2008; 88: 589–93.

386. Carlin CS, Callis KP, Krueger GG. Efficacy of acitretin and commercial tanning bed therapy for psoriasis. Arch Dermatol. 2003; 139: 436–42.

387. Berbis P, Geiger JM, Vaisse C, Rognin C, Privat Y. Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis. Dermatologica. 1989; 178: 88–92.

388. Lebwohl M. Acitretin in combination with UVB or ПУФА. J Am Acad Dermatol. 1999; 41: 22–4.

389. Lowe NJ, Prystowsky JH, Bourget T, Edelstein J, Nychay S, Armstrong R. Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol. 1991; 24: 591–4.

390. Gronhoj Larsen F, Steinkjer B, Jakobsen P, Hjorter A, Brockhoff PB, Nielsen-Kudsk F. Acitretin is converted to etretinate only during concomitant alcohol intake. Br J Dermatol. 2000; 143: 1164–9.

391. Murray HE, Anhalt AW, Lessard R, Schacter RK, Ross JB, Stewart WD, Geiger JM. A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter study. J Am Acad Dermatol. 1991; 24: 598–602.

392. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB. Efficacy and safety of ustekinumab, a human interleukin- 12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 1). Lancet. 2008; 371: 1665–74.

393. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 2). Lancet. 2008; 371: 1675–84.

394. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009; 373: 633–40.

395. Matz H, Orion E, Wolf R. Balneotherapy in dermatology. Dermatol Ther. 2003; 16: 132–40.

396. Cohen AD, Shapiro J, Michael D, Hodak E, Van-Dijk D, Naggan L, Vardy DA. Outcome of “short-term” Dead Sea climatotherapy for psoriasis. Acta Derm Venereol. 2008; 88: 90–1.

397. Harari M, Novack L, Barth J, David M, Friger M, Moses SW. The percentage

of patients achieving PASI 75 after 1 month and remission time after climatotherapy at the Dead Sea. Int J Dermatol. 2007; 46: 1087–91.

398. Kushelevsky AP, Harari M, Hristakieva E, Shani J. Climatotherapy of psoriasis

and hypertension in elderly patients at the Dead-Sea. Pharmacol Res. 1996; 34: 87–91.

399. Schmid-Ott G. Depth psychologyfounded psychotherapy of psoriatic patients. Treatment of a patient with chronic recidivating psoriasis vulgaris. Dermatol Psychosom. 2000; 1: 112–6.

400. Gupta MA, Gupta AK, Kirkby S, Schork NJ, Gorr SK, Ellis CN, Voorhees JJ. A psychocutaneous profile of psoriasis patients who are stress reactors. A study of 127 patients. Gen Hosp Psychiatry. 1989; 11: 166–73.

401. Augustin M, Amon U, Bullinger M, Gieler U. Empfehlungen zur Erfassung

von Lebensqualität in der Dermatologie. Dermatol Psychosom. 2000; 1: 76–82.

402. De Korte J, Mombers FM, Sprangers MA, Bos JD. The suitability of quality-

of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol. 2002; 138: 1221–7; discussion 27.

403. Finlay AY, Khan GK, Luscombe DK, Salek MS. Validation of Sickness Impact

Profile and Psoriasis Disability Index in Psoriasis. Br J Dermatol. 1990; 123: 751–6.

404. Schmid-Ott G, Keins P, Fartasch M, Ring J, Lob-Corzilius T, von Rüden U, Wolf P. Atopic eczema prevention program in childhood and adolescence – a model project of the German government. Dermatol Psychosom. 2000; 1: 179–82.

405. Schmid-Ott G, Jaeger B, Adamek C, Koch H, Lamprecht F, Kapp A, Werfel T. Levels of circulating CD8(+) T lymphocytes, natural killer cells, and eosinophils increase upon acute psychosocial stress in patients with atopic dermatitis. J Allergy Clin Immunol. 2001; 107: 171–7.

406. Fortune DG, Richards HL, Kirby B, Bowcock S, Main CJ, Griffiths CE. A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol. 2002; 146: 458–65.

407. Tausk F, Whitmore SE. A pilot study of hypnosis in the treatment of patients with psoriasis. Psychother Psychosom. 1999; 68: 221–5.

408. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67: 361–70.

409. Hacker SM, Rasmussen JE. The effect of flash lamp-pulsed dye laser on psoriasis. Arch Dermatol. 1992; 128: 853–5.

410. Ilknur T, Akarsu S, Aktan S, Ozkan S. Comparison of the effects of pulsed dye laser, pulsed dye laser + salicylic acid, and clobetasole propionate + salicylic acid on psoriatic plaques. Dermatol Surg. 2006; 32: 49–55.

411. Taibjee SM, Cheung ST, Laube S, Lanigan SW. Controlled study of excimer and pulsed dye lasers in the treatment of psoriasis. Br J Dermatol. 2005; 153: 960–6.

412. Trott J, Gerber W, Hammes S, Ockenfels HM. The effectiveness of ПУФА treatment in severe psoriasis is significantly increased by additional UV 308-nm excimer laser sessions. Eur J Dermatol. 2008; 18: 55–60.

413. Martin-Ezquerra G, Sanchez-Regana M, Umbert-Millet P. Optimization of narrow-band uvb with a 5 % oleic acid cream in the treatment of psoriasis. J Drugs Dermatol. 2007; 6: 290–2.

414. Orfanos CE, Steigleder GK, Pullmann H, Bloch PH. Oral retinoid and UVB radiation: a new, alternative treatment for psoriasis on an out-patient basis. Acta Derm Venereol. 1979; 59: 241–4.

415. Lotti T, Tripo L, Grazzini M, Krysenka A, Buggiani G, De Giorgi V. Focused UV-B narrowband microphototherapy (Biopsorin). A new treatment for plaque psoriasis. Dermatol Ther. 2009; 22: 383–5.

416. Peroni A, Gisondi P, Zanoni M, Girolomoni G. Balneotherapy for chronic plaque psoriasis at Comano spa in Trentino, Italy. Dermatol Ther. 2008; 21 Suppl 1: S31–8.

417. Halevy S, Giryes H, Friger M, Sukenik H. Dead sea bath salt for the treatment of psoriasis vulgaris: A double-blind controlled study. J Eur Acad Dermatol Venereol. 1997; 9: 237–42.

418. Calzavara-Pinton P. Narrow band UVB (311 nm) phototherapy and ПУФА photochemotherapy: a combination. J Am Acad Dermatol. 1998; 38: 687–90.

419. Markham T, Rogers S, Collins P. Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen-UV-A for the treatment of chronic plaque psoriasis. Arch Dermatol. 2003; 139: 325–8.

420. ul Bari A, Iftikhar N, ber Rahman S. Comparison of ПУФА and UVB therapy in moderate plaque psoriasis. J Pak Assoc Dermatol. 2005: 26–31.

421. Serwin AB, Chodynicka B. Soluble tumour necrosis factor-alpha receptor type 1 as a biomarker of response to phototherapy in patients with psoriasis. Biomarkers. 2007; 12: 599–607.

422. Calzavara-Pinton P, Ortel B, Carlino A, Honigsmann H, De Panfilis G. A reappraisal of the use of 5-methoxypsoralen in the therapy of psoriasis. Exp Dermatol. 1992; 1: 46–51.

423. Henseler T, Wolff K, Honigsmann H, Christophers E. Oral 8-methoxypsoralen photochemotherapy of psoriasis. The European ПУФА study: a cooperative study among 18 European centres. Lancet. 1981; 1: 853–7.

424. Kaur J, Sharma VK, Sethuraman G, Tejasvi T. Comparison of the efficacy of psoralen ultraviolet A with narrowband ultraviolet B phototherapy for the treatment of chronic plaque psoriasis in patients with skin types IV and V. Clin Exp Dermatol. 2008; 33: 513–5.

425. Torras H, Aliaga A, Lopez-Estebaranz JL, Hernandez I, Gardeazabal J, Quintanilla E, Mascaro JM. A combination therapy of calcipotriol cream and ПУФА reduces the UVA dose and improves the response of psoriasis vulgaris. J Dermatolog Treat. 2004; 15: 98–103.

426. Valbuena MC, Hernandez O, Rey M, Sanchez G, de Quintana LP. Twice- vs. thrice-weekly MPD ПУФА in psoriasis: a randomized-controlled efficacy study. Photodermatol Photoimmunol Photomed. 2007; 23: 126–9.

427. Smith CH, Jackson K, Bashir SJ, Perez A, Chew AL, Powell AM, Wain M, Barker JN. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Br J Dermatol. 2006; 155: 160–9.

428. Vena GA, Cassano N, Agnusdei CP, Bellini M, Calabretta S, Centofani S, Cervadoro G, Coviello C, Curia S, Dattola S, de Caro C, del Brocco L, Donato L, Favero L, Ferrari A, Gianfaldoni R, Liguori G, Loconsole F, Lopreiato R, Malara G, Massimino SD, Nannipieri A, Pettinato M, Postiglione D, Postorioni C, Pronesti ME, Provenzano E, Puglisi Guerra A, Ricciuti F, Ruggiero G, Scudero A, Spitaleri S, Trinca Armati F, Valenti G, Vernaci R, Verrina F, Zagni GF, Zappala F. Treatment of psoriasis vulgaris with calcipotriol betamethasone dipropionate combination followed by calcipotriol and assessment of the adjuvant basic use of urea-based emollients. Eur J Inflamm. 2005; 3: 37–41.

429. Magliocco MA, Pandya K, Dombrovskiy V, Christiansen L, Wong Y, Gottlieb AB. A randomized, doubleblind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1 % versus vehicle gel in combination with narrowband UVB phototherapy for moderate to severe psoriasis vulgaris. J Am Acad Dermatol. 2006; 54: 115–8.